GAITHERSBURG, Md. — March 4, 2026 — Leads & Copy — Elutia Inc. (Nasdaq: ELUT) has received notification from Nasdaq that it has regained compliance with the minimum bid price and minimum market value of listed securities requirements.
According to Nasdaq Listing Rules 5550(a)(2) and 5550(b)(2), Elutia is now in full compliance with all Nasdaq continued listing requirements. Nasdaq has confirmed that these matters are now closed, and the Company’s Class A common stock will continue to be listed and traded on the Nasdaq Capital Market under the symbol “ELUT.”
Matt Ferguson, Chief Financial Officer of Elutia, expressed satisfaction with the regained compliance, citing investors’ confidence in the company’s drug-eluting biomatrix technology platform, the market opportunity, and the Elutia CRU’s capabilities as contributing factors to the recent increase in share price and market value.
Elutia develops and commercializes drug-eluting biomatrix products aimed at improving the compatibility between medical devices and patients. The company’s mission is to humanize medicine, enabling patients to thrive without compromise, particularly given the growing need for implantable technologies.
Source: Elutia
